Ana Pamplona, PhD,  —

Ana holds her PhD in Biochemistry from the Faculty of Science and Technology from Lisbon (UNL). She has worked in the T-cell differentiation and Tumor targeting Lab at Instituto de Medicina Molecular, headed by Prof. Bruno Silva-Santos, and has served as a scientific reviewer for the peer-reviewed journal Infection & Immunity.

Articles by Ana Pamplona

Clinic-based CF Study Links Repeat Hospitalizations to Repeat MRSA Infections

A new study of children with cystic fibrosis found that co-infection with methicillin-resistant bacteria may be associated with increased pulmonary morbidity, especially in children with repeat hospitalizations. The retrospective study, conducted at a U.S. pediatric medical center with high rates of methicillin-resistant respiratory infections, is titled “Clinical characteristics and…

Targeted Antibiotics Focus of New Cystic Fibrosis Study

A new study entitled “Lung Microbiota Changes Associated with Chronic Pseudomonas aeruginosa Lung Infection and the Impact of Intravenous Colistimethate Sodium,” published in the PLOS One journal, highlights the potentially positive impact of intravenous antibiotic colistimethate sodium in the proportion of Pseudomonadales relative to other Gram-negative…

Managing the Steps in Cystic Fibrosis Pulmonary Flare-ups

A new study entitled “Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention,” published in The International Society for Microbial Ecology Journal, investigated how bacterial communities in the lung change over time in relation to the disease state and progression of…

CF Protein Tied to Intestinal Inflammation in Study

A new study revealed that the cystic fibrosis transmembrane conductance regulator (CFTR) plays an important role in regulating the intestinal inflammatory responses. The study, entitled “CFTR Knockdown induces pro inflammatory changes in intestinal epithelial cells,” was published in the Journal of Inflammation…

CF Pathogen Defies Treatment Attempt with Novel Drug Combination

A new study revealed that treating P. aeruginosa biofilms with the antibiotic tobramycin together with mannitol — two well-known therapies in treating lung infections in CF — did not reduce overall bacterial load. The study entitled “Mannitol Does Not Enhance Tobramycin Killing of Pseudomonas aeruginosa in a Cystic Fibrosis Model System…

Your CF Community


Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.